Granulocyte elastase-α1-antiproteinase complex in cystic fibrosis: Sensitive plasma assay for monitoring pulmonary infections

Hollsing, Annika; Lantz, Bo M.T.; Bergström, Kurt; Malmborg, Anna‐Stina; Strandvik, Birgitta

doi:10.1016/s0022-3476(87)80068-9

Cited by 34 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…C-reactive protein and the elastase-a 1 -antiprotease complex are frequently increased during exacerbations and fall after antibiotic therapy. However, a wide variability within and between patients has been observed in long-term studies [63]. Two inflammatory markers in urine, LTE 4 and desmosine (a break-down product of elastin), have been advocated as surrogate markers, but their variability is also high in long-term studies [64,65].…”

Section: Inflammatory Response Markers In Cystic Fibrosismentioning

confidence: 99%

Mechanisms and markers of airway inflammation in cystic fibrosis: Fig. 1.—

Rose¹

2002

Eur Respir J

View full text Add to dashboard Cite

Section: Inflammatory Response Markers In Cystic Fibrosismentioning

confidence: 99%

Mechanisms and markers of airway inflammation in cystic fibrosis: Fig. 1.—

Rose¹

2002

Eur Respir J

View full text Add to dashboard Cite

“…Active HLE, from the respiratory epithelial surface, spills over into the blood where it is rapidly inactivated by α1AT and forms a complex that can be detected in the plasma. HLE and α1AT complexes (pHLE complexes) are increased in CF plasma, suggesting that neutrophil granule products may represent useful markers of CF pulmonary in ammation and infections [19][20][21][22]. Despite these and other reports, the pHLE complex has not been widely used as a biomarker for CF lung disease.…”

mentioning

confidence: 99%

Plasma biomarkers and cystic fibrosis lung disease

Cantin

Bilodeau²,

Larivée³

et al. 2012

CIM

View full text Add to dashboard Cite

Plasma biomarkers and cystic brosis lung disease AbstractPurpose: e purpose of this study was to determine whether plasma biomarkers re ect changes in lung function and respiratory exacerbations associated with CF lung disease.Methods: Plasma human leukocyte elastase/alpha1 antitrypsin complex (pHLE complex) values were measured in 28 adult CF patients and 47 healthy volunteers and correlated with forced expiratory volume (FEV1) and forced vital capacity (FVC). pHLE complexes were studied during respiratory exacerbations and a er antibiotic therapy. Plasma cytokines and sialic acid were also measured.Results: pHLE complexes were increased in CF patients (p < 0.01), were inversely correlated with FEV1 (r = 0.71) and FVC (r = 0.67) and returned to normal levels a er intravenous antibiotics (p < 0.001). Plasma cytokines did not correlate with lung function. Total sialic acid increased during CF respiratory exacerbations and decreased a er antibiotic therapy.Conclusion: Plasma sialic acid and pHLE complexes re ect clinically meaningful changes in CF lung disease. In contrast, plasma cytokine levels did not correlate with lung function.

show abstract

“…Although all strategies rely on a combination of mucus-dissolving agents, passive or active physical activities and antibiotics, success varies greatly both between countries and centers [31] . Most attention has been paid to the chronic colonization with Pseudomonas aeruginosa, although the more or less chronic colonization with Staphylococcus aureus, which usually precedes the former, gives a much higher respiratory burst and therefore is also more tissue aggressive [32] . There is a general risk that the fear of Pseudomonas colonization, which demands intravenous antibiotic administration, causes a unconscious neglect to treat S. aureus .…”

Section: Therapy Of Lung Diseasementioning

confidence: 99%

Care of Patients with Cystic Fibrosis

Strandvik

2006

Ann Nestlé [Engl]

Self Cite

View full text Add to dashboard Cite

Cystic fibrosis (CF), the most common autosomal hereditary pediatric disease, is no longer restricted to childhood as modern therapy has given patients both increased longevity and better quality of life. When the gene was identified more than 16 years ago and the most common mutation, ΔF508, found, general hope of a rapid cure for the disease was expressed. The discovery entailed a marked increase in research on pathophysiology, but to date the improvements in clinical therapy are entirely due to developments in traditional treatment. Improvements in the patient’s condition are related to better pancreatic enzyme supplements and more intense nutritional treatment, including the attention paid to abnormal lipid metabolism. Pulmonary treatment has resulted in better preserved lung function into adulthood with access to a battery of efficient antibiotics and the development of new strategies; mucus-dissolving agents in combination with encouragement of physical activity from an early age together with modifications in physiotherapy, and improved results in lung transplantations as the ultimate treatment. Liver disease is recognized more, and often treated long-term with ursodeoxycholic acid, although its effect in preventing progression of liver disease has not been fully explored. Neonatal screening is increasing, challenging short-term problems such as those of a psychological nature when carriers or very mild diseases are discovered, and exploring long-term results to prove that clinical status improves and survival further increases. The limitations in survival still present seem mainly to be due to the mystery behind the chronic colonization of the airways by microorganisms.

show abstract

Granulocyte elastase-α1-antiproteinase complex in cystic fibrosis: Sensitive plasma assay for monitoring pulmonary infections

Cited by 34 publications

References 18 publications

Mechanisms and markers of airway inflammation in cystic fibrosis: Fig. 1.—

Mechanisms and markers of airway inflammation in cystic fibrosis: Fig. 1.—

Plasma biomarkers and cystic fibrosis lung disease

Care of Patients with Cystic Fibrosis

Contact Info

Product

Resources

About